Delavirdine: Difference between revisions
Created page with " {{intro}} Delavirdine is a nonnucleoside reverse transcriptase inhibitor used in combination with other agents in the therapy of human immunodeficiency virus (HIV) infect..." |
CSV import |
||
| Line 16: | Line 16: | ||
{{antiviral agents}} | {{antiviral agents}} | ||
{{coststubd}} | {{coststubd}} | ||
<gallery> | |||
File:Delavirdine.svg|Chemical structure of Delavirdine | |||
File:Delavirdine_ball-and-stick_model.png|Ball-and-stick model of Delavirdine | |||
File:Delavirdine_synthesis.png|Synthesis pathway of Delavirdine | |||
</gallery> | |||
Latest revision as of 01:33, 18 February 2025
Information about Delavirdine[edit]
Delavirdine is a nonnucleoside reverse transcriptase inhibitor used in combination with other agents in the therapy of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS).
Liver safety of Delavirdine[edit]
Delavirdine is associated with a low rate of transient serum aminotransferase elevations during therapy and is a rare cause of clinically apparent acute liver injury.
Mechanism of action of Delavirdine[edit]
Delavirdine (del a' vir deen) is an antiretroviral agent that acts by noncompetitive binding to and inhibition of the HIV reverse transcriptase. Delavirdine is a nonnucleoside reverse transcriptase inhibitor and is similar to nevirapine, efavirenz, etravirine and rilpivirine in its mechanism of action, but shares minimal structural features with the other antiviral agents in this class. Delavirdine in combination with other antiretroviral agents lowers HIV RNA levels and delays onset of AIDS related complications.
FDA approval information for Delavirdine[edit]
Delavirdine was approved by the FDA in 1998 and current indications are for the treatment of HIV infection in combination with other HIV medications.
Dosage and administration for Delavirdine[edit]
Delavirdine is available under the brand name Rescriptor in tablets of 100 and 200 mg. The recommended dose of delavirdine is 400 mg orally three times daily. Because of its requirement for thrice daily dosing, delavirdine is not widely used. Common side effects include fatigue, dizziness, headache, and skin rashes.
Antiviral agents[edit]
Drugs for HIV Infection, in the Subclass Antiretroviral Agents
- Fusion Inhibitors (HIV)
- Integrase Inhibitors (HIV)
- Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
- Interferon Based Therapies
HCV NS5A Inhibitors
HCV NS5B (Polymerase) Inhibitors
- Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir
Combination Therapies
Drugs for Herpes Virus Infections (HSV, CMV, others)
Drugs for Influenza
-
Chemical structure of Delavirdine
-
Ball-and-stick model of Delavirdine
-
Synthesis pathway of Delavirdine